Windham Venture Partners

TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data set to create actionable insights.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Clever Care Health Plan, Inc. is a healthcare insurance provider that specializes in Medicare Advantage plans, integrating the principles of Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers a range of culturally sensitive healthcare solutions. Its plans include access to services such as acupuncture, herbal remedies, tai chi, and cupping, aimed at enhancing both physical and mental well-being. Clever Care connects its members with diverse networks of hospitals and healthcare providers who are attuned to their cultural needs and language preferences. The company distributes its products through brokers and sales agents, ensuring that Medicare beneficiaries receive the support and services they require.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

SubjectWell is a clinical trial marketplace focused on patient recruitment, providing a risk-free platform for healthcare clients to efficiently find and screen qualified participants for clinical trials. By streamlining the recruitment process, SubjectWell helps accelerate the completion of studies, ensuring that healthcare organizations can meet their research timelines effectively. The company specializes in delivering highly qualified referrals, thereby enhancing the overall efficiency of clinical trials and contributing to advancements in medical research.

Valera Health, established in 2015, operates a behavioral healthcare platform focused on delivering personalized mental health services to individuals with a range of conditions from mild to severe, including depression and schizophrenia. The company integrates digital technology and data science with traditional clinical services to enhance patient outcomes and address the needs of hard-to-reach populations. By providing a comprehensive approach that combines therapy, medication, and continuous connectivity with care teams, Valera Health aims to offer efficient mental healthcare solutions, particularly for employers seeking to improve access to mental health support for their employees.

Vergent Bioscience, Inc. specializes in developing tumor-targeted fluorescent probes that enhance the surgical removal of cancerous tissue. Founded in 2013 and based in Minneapolis, Minnesota, the company’s flagship product, VGT-309, is a molecularly-targeted imaging molecule designed to bind to enzymes overexpressed in various tumor tissues. Upon injection before surgery, VGT-309 activates a brightly fluorescing dye, enabling surgeons to visually distinguish cancerous tissue from normal tissue during procedures. This technology aims to improve surgical outcomes by ensuring the complete removal of tumors, which is crucial for increasing cure rates. Vergent Bioscience's innovative approach addresses a significant clinical need for advanced visualization in various surgical settings, including open, laparoscopic, and robotic surgeries.

Upward Health Inc. is a specialty care coordination organization that focuses on home-based medical and behavioral care for individuals facing mental illness and substance abuse disorders. Established in 2017 and based in Providence, Rhode Island, the company collaborates with health plans and providers to ensure comprehensive support for patients with complex needs. By coordinating care among caregivers, primary care physicians, and various medical and behavioral health specialists, Upward Health aims to facilitate full recovery and safe transitions back to the community. The organization emphasizes hands-on, holistic care, which not only improves health outcomes for high-risk members but also reduces overall healthcare costs. Upward Health was previously known as BehaveCare Inc. before rebranding in July 2019.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Valera Health, established in 2015, operates a behavioral healthcare platform focused on delivering personalized mental health services to individuals with a range of conditions from mild to severe, including depression and schizophrenia. The company integrates digital technology and data science with traditional clinical services to enhance patient outcomes and address the needs of hard-to-reach populations. By providing a comprehensive approach that combines therapy, medication, and continuous connectivity with care teams, Valera Health aims to offer efficient mental healthcare solutions, particularly for employers seeking to improve access to mental health support for their employees.

Clever Care Health Plan, Inc. is a healthcare insurance provider that specializes in Medicare Advantage plans, integrating the principles of Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers a range of culturally sensitive healthcare solutions. Its plans include access to services such as acupuncture, herbal remedies, tai chi, and cupping, aimed at enhancing both physical and mental well-being. Clever Care connects its members with diverse networks of hospitals and healthcare providers who are attuned to their cultural needs and language preferences. The company distributes its products through brokers and sales agents, ensuring that Medicare beneficiaries receive the support and services they require.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Upward Health Inc. is a specialty care coordination organization that focuses on home-based medical and behavioral care for individuals facing mental illness and substance abuse disorders. Established in 2017 and based in Providence, Rhode Island, the company collaborates with health plans and providers to ensure comprehensive support for patients with complex needs. By coordinating care among caregivers, primary care physicians, and various medical and behavioral health specialists, Upward Health aims to facilitate full recovery and safe transitions back to the community. The organization emphasizes hands-on, holistic care, which not only improves health outcomes for high-risk members but also reduces overall healthcare costs. Upward Health was previously known as BehaveCare Inc. before rebranding in July 2019.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Valera Health, established in 2015, operates a behavioral healthcare platform focused on delivering personalized mental health services to individuals with a range of conditions from mild to severe, including depression and schizophrenia. The company integrates digital technology and data science with traditional clinical services to enhance patient outcomes and address the needs of hard-to-reach populations. By providing a comprehensive approach that combines therapy, medication, and continuous connectivity with care teams, Valera Health aims to offer efficient mental healthcare solutions, particularly for employers seeking to improve access to mental health support for their employees.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.

ControlRad is focused on creating innovative solutions aimed at significantly reducing radiation exposure risks associated with both fixed and mobile C-arm procedures for patients and healthcare professionals. The company's devices are designed to minimize ionizing radiation during fluoroscopically guided interventional procedures, ensuring that image quality and workflow are not compromised. ControlRad employs an add-on solution for C-arms that utilizes an eye tracker and a tablet interface, allowing radiologists to achieve optimal image quality in the critical areas of interest while maintaining clarity in the surrounding regions. This approach enables healthcare providers to enhance patient safety without sacrificing the effectiveness of existing x-ray systems.

RxWare is a SaaS company founded in 2013 that focuses on enhancing the patient experience for pharmaceutical drug manufacturers. The company offers a digital infrastructure that connects various components of the patient journey, simplifying the process for patients accessing therapy. Its Patient Gateway integrates with existing patient services, including ePrescribing systems, specialty pharmacies, and affordability solutions, facilitating improved resource utilization and therapy outcomes. RxWare's platform is designed to transform complex patient pathways into streamlined experiences, allowing drug manufacturers to optimize and accelerate patient journeys effectively.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, founded in 2012. The company specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) by utilizing patented mathematical methods and algorithmic enhancements. ChromaCode's products significantly enhance the multiplexing capabilities of quantitative polymerase chain reaction (qPCR) instruments, allowing laboratories to perform cost-effective testing of multiple targets from a single sample. Their offerings include software, reagents, and assays that improve signal processing and overall assay performance, making diagnostics more accessible and efficient. Among their notable products is the HDPCR Tick-Borne Pathogen Panel, a multiplex test that detects various tick-borne pathogens in one assay.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

SubjectWell is a clinical trial marketplace focused on patient recruitment, providing a risk-free platform for healthcare clients to efficiently find and screen qualified participants for clinical trials. By streamlining the recruitment process, SubjectWell helps accelerate the completion of studies, ensuring that healthcare organizations can meet their research timelines effectively. The company specializes in delivering highly qualified referrals, thereby enhancing the overall efficiency of clinical trials and contributing to advancements in medical research.

Andros is an NCQA certified credentialing and provider data management solution that integrates software and services to enhance efficiency in the healthcare sector. The company provides its clients with significant improvements in credentialing processes, boasting a tenfold reduction in turnaround times and a fifteenfold increase in overall efficiency compared to industry norms. Andros aims to assist payers and provider organizations in mitigating compliance risks, streamlining operations, and enhancing the management of their provider networks, ultimately contributing to more effective healthcare delivery.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.

NeoTract, Inc. is a medical device company specializing in minimally invasive solutions for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, it develops the UroLift system, which is specifically designed for men suffering from enlarged prostate. This system addresses symptoms effectively while preserving normal sexual function. NeoTract serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, the company is committed to providing innovative clinical devices that improve patient outcomes in urology and gynecology.

Science Exchange, Inc. operates an online marketplace that facilitates collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and based in Palo Alto, California, the company enables users to search for, compare, and procure scientific services from U.S. research institutions, streamlining the process of obtaining quotes, managing projects, and processing payments. The platform enhances research and development productivity by automating various collaborative tasks while ensuring data security and regulatory compliance. By matching researchers seeking to outsource experiments with qualified service providers, Science Exchange makes it easier and more affordable for scientific institutions and researchers to access outsourced research and development services, ultimately accelerating the pace of scientific discovery.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

GlySens Incorporated is a privately held company focused on creating an innovative long-term continuous glucose monitoring system aimed at enhancing the lives of individuals with diabetes. The company's implantable sensor has demonstrated an impressive lifespan of up to 18 months in preclinical testing and wirelessly connects to an external receiver for real-time glucose measurement, recording, and alerts for hypo- and hyperglycemic events. Unlike other glucose monitoring systems that require frequent calibrations, the GlySens sensor is designed for infrequent calibration checks, minimizing the burden on users. This technology aims to provide a seamless and unobtrusive monitoring experience, allowing individuals to manage their diabetes more effectively and maintain their lifestyle. The GlySens ICGM system is currently in clinical evaluation, with initial human trials completed and preparations for further trials underway.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Cureatr Inc. is a New York-based company that specializes in mobile care coordination solutions for healthcare providers. Founded in 2011, it offers a cloud-based medication management software designed to optimize patient care, particularly focusing on post-discharge medication reconciliation. The platform combines HIPAA-secure text messaging with workflow navigation tools, facilitating communication and coordination among healthcare professionals. Cureatr's software features an inbuilt dashboard that curates and analyzes patients' medication history, enabling providers to respond to real-time events and improve their interactions with patients. By streamlining these processes, Cureatr enhances the overall quality of patient care.

Coravin, Inc. specializes in designing and marketing innovative wine access systems for a variety of customers, including wine enthusiasts, restaurants, wine stores, and wineries. Founded in 2011 and based in Burlington, Massachusetts, the company offers a unique technology that allows users to pour wine by the glass without removing the cork, thereby preserving the wine's quality and aging process. Their product line includes the Coravin Wine Preservation Opener, along with various accessories such as wine access needles, capsules, clamps, and carry cases. This technology enables customers to enjoy fine wines without committing to an entire bottle, ensuring that the wine remains sealed and protected from air and moisture.

ClarVista Medical, Inc. is a California-based company that specializes in developing innovative products for ophthalmic conditions. Founded in 2012 as a spin-off from a medical device incubator, the company focuses on its flagship product, the HARMONI modular intraocular lens system. This system is designed to optimize vision during cataract surgery by allowing for the initial positioning of the lens and the easy exchange of the lens optic, thus enabling healthcare practitioners to tailor procedures to meet individual patient needs. ClarVista Medical has established a robust portfolio of intellectual property and has conducted clinical studies to validate its technology. The company has secured significant funding to advance the development of the HARMONI system and to pursue necessary regulatory approvals.

Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.

Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.

VytronUS, Inc. specializes in the manufacture and marketing of cardiac medical devices aimed at treating cardiac arrhythmias. Founded in 2006 and located in Sunnyvale, California, the company focuses on leveraging ultrasound energy to enhance the imaging and therapeutic capabilities of its devices. These innovative products allow for precise non-contact energy delivery and facilitate the production of high-resolution maps of cardiac anatomy. By providing physicians with tools that enable visualization, precision, flexibility, and automation, VytronUS aims to improve the treatment of complex arrhythmias.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company specializes in a minimally invasive intracanalicular scaffold that alleviates high intraocular pressure by restoring the natural outflow pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its primary focus on glaucoma, Ivantis intends to explore innovative treatments for other ophthalmic diseases as it expands its product offerings. The company also provides a Session Persistence Server to support clinical trials, ensuring data protection for telnet task workers and terminal emulation users across various devices and operating systems.

RxWare is a SaaS company founded in 2013 that focuses on enhancing the patient experience for pharmaceutical drug manufacturers. The company offers a digital infrastructure that connects various components of the patient journey, simplifying the process for patients accessing therapy. Its Patient Gateway integrates with existing patient services, including ePrescribing systems, specialty pharmacies, and affordability solutions, facilitating improved resource utilization and therapy outcomes. RxWare's platform is designed to transform complex patient pathways into streamlined experiences, allowing drug manufacturers to optimize and accelerate patient journeys effectively.

Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

NeoTract, Inc. is a medical device company specializing in minimally invasive solutions for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, it develops the UroLift system, which is specifically designed for men suffering from enlarged prostate. This system addresses symptoms effectively while preserving normal sexual function. NeoTract serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, the company is committed to providing innovative clinical devices that improve patient outcomes in urology and gynecology.

Welldoc, Inc. specializes in developing technology solutions for chronic disease management, focusing primarily on diabetes care. Its flagship product, the DiabetesManager platform, allows patients and healthcare providers to coordinate care effectively, promoting self-management and adherence to treatment. This platform includes features such as personalized coaching, medication reminders, out-of-bound alerts, and cloud-based analytics for tracking health metrics. Additionally, Welldoc offers BlueStar, a mobile prescription therapy that provides real-time guidance for diabetes management and clinical decision support for healthcare professionals. The company collaborates with various stakeholders, including payors, employers, pharmaceutical firms, and healthcare systems, to ensure its solutions integrate seamlessly into existing workflows. Founded in 2005 and based in Baltimore, Maryland, with additional offices in Wilmington, Delaware, and Bengaluru, India, Welldoc aims to transform digital health management through innovative technology and artificial intelligence.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

NeoTract, Inc. is a medical device company specializing in minimally invasive solutions for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, it develops the UroLift system, which is specifically designed for men suffering from enlarged prostate. This system addresses symptoms effectively while preserving normal sexual function. NeoTract serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, the company is committed to providing innovative clinical devices that improve patient outcomes in urology and gynecology.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

Transactis, Inc. specializes in Software-as-a-Service (SaaS) solutions for electronic bill presentment and payment, primarily serving businesses in the United States. The company offers BillerIQ, a cloud-based platform that allows businesses to send electronic bills and invoices while facilitating payments through online, phone, and mobile channels. Additionally, Transactis provides DocumentIQ, a digital document management solution that helps organizations manage and store documents electronically. Its services cater to various sectors, including financial services, healthcare, utilities, education, and retail, among others. Transactis operates through a reseller network that includes financial institutions and technology companies, positioning itself as a comprehensive partner by providing sales, marketing, and operational support to enhance resellers' offerings. The company adheres to stringent regulatory standards, ensuring compliance with industry requirements. Founded in 2001 and headquartered in New York, Transactis operates as a subsidiary of Mastercard Incorporated.

NeoTract, Inc. is a medical device company specializing in minimally invasive solutions for urological disorders. Founded in 2004 and headquartered in Pleasanton, California, it develops the UroLift system, which is specifically designed for men suffering from enlarged prostate. This system addresses symptoms effectively while preserving normal sexual function. NeoTract serves a diverse customer base across the United States, Europe, Australia, Canada, Mexico, and South Korea. As a subsidiary of Teleflex Urology Limited, the company is committed to providing innovative clinical devices that improve patient outcomes in urology and gynecology.